Nurse Practitioner Registered
Resume:
CURRICULUM VITAE
NICOLE HANS, CNP, RN, MS
Chesapeake, VA 23323
Phone: 757-***-****
Email: *******@*****.***
OBJECTIVE__________________________________________________________________________
To obtain a nurse practitioner position in which I can utilize my academic knowledge and clinical and work experiences to benefit the hiring practice.
EDUCATION
THE OHIO STATE UNIVERSITY, COLUMBUS, OHIO
Masters Degree in Adult Health and Illness Nurse Practitioner, December 2001
THE OHIO STATE UNIVERSITY, COLUMBUS, OHIO
Baccalaureate Degree in Nursing, June, 1997
LICENSES
Adult Nurse Practitioner, APRN, ANCC Board Certified
Virginia and Ohio Licensed Nurse Practitioner
Licensed Registered Nurse, The Virginia and Ohio Board of Nursing License Virginia and Ohio
Authorization to Prescribe
Completion of externship for prescriptive authority
Drug Enforcement Agency Licensure
Member of ACRP for research professional
2007 Completion of CITI Course in The Protection of Human Research Subjects
WORK EXPERIENCE
SENTARA MEDICAL GROUP, VIRGINIA BEACH, VIRGINIA
Adult Nurse Practitioner and Research Supervisor, July 2009-July 2012
provide follow-up patient care in the neurology division with a sub-specialty in
Movement Disorders
Sub-Investigator for clinical trials for Parkinson’s Disease patients
THE OHIO STATE UNIVERSITY MEDICAL CENTER, COLUMBUS, OHIO
Adult Nurse Practitioner and Research Coordinator/Supervisor, July 2006-June 2009
Provide emergency patient care and follow-up visits in the Movement Disorder
Division
Assists with clinical trials for Parkinson’s Disease patients.
CENTRAL OHIO PRIMARY CARE PHYSICIANS, COLUMBUS, OHIO
Adult Nurse Practitioner, July 2002-2006
Independently providing medical management to a wide variety of
patients in a family practice setting under indirect supervision of
three collaborating physicians; ability to diagnose, assess, plan,
treat, prescribe, and evaluate both acute and chronic illness.
MOUNT CARMEL WEST MEDICAL CENTER, COLUMBUS, OHIO
Staff Nurse, Medical Intensive Care Unit, June 2001-July 2002
Intensive monitoring of critically ill patients in a nine bed unit;
providing numerous life saving measures that include ventilator
support, intravenous drips, cardiac monitoring, and ACLS measures.
THE OHIO STATE UNIVERSITY MEDICAL CENTER, COLUMBUS, OHIO
Staff Nurse, Surgical Intensive Care Unit, June 1997-February 2001
Intensive monitoring of stable and unstable patients in a 44 bed unit;
supplying medications and intravenous fluids, detailed assessments
and a variety of procedures to a wide range of surgical patients including
burn, neuro, trauma, cardiac, transplant and general surgery patients.
THE OHIO STATE UNIVERISTY MEDICAL CENTER, COLUMBUS, OHIO
Student Nurse Associate, Dodd Hall, December 1995-June 1997
Rehabilitation unit-vital signs, weighing patients, hygiene care, EKG’s
phlebotomy, trach and G-tube care, suctioning, and charting.
CURRENT AND PAST RESEARCH EXPERIENCES
Sub-Investigator. A multi-centered, opened-label study to assess the long-
term safety of droxidopa in subjects with primary autonomic failure,
dopamine beta hydroxylase deficiency or non-diabetic neuropathy and
symptomatic neurogenic orthostatic hypotension. June 2011-present.
Sub-Investigator. A multi-center, open-label extension study to examine
safety and tolerability of ACP-103 in the treatment of psychosis in
Parkinson’s Disease. September 2010.
Sub-Investigator. A multicenter, double-blind, randomized, parallel-group,
placebo-controlled study to assess the clinical effect of droxidopa in the
treatment of symptomatic neurogenic orthostatic hypotension in patients with
parkinson's disease. May 2010-ongoing.
. Sub-Investigator. A Multi-Center, Placebo-Controlled, Double-Blind Trial
to examine the safety and efficacy of Pimavanserin in the Treatment of
Psychosis in Parkinson’s disease. May 2010-ongoing.
Sub-Investigator. Ipsen. A randomized, double-blind, placebo-controlled, study
of the efficacy and safety of Trimethobenzamide(Tigan) in the control of nausea and
vomiting during initiation and continued treatment with continuous apomorphine
(Apoken) in apomorphine-naïve subjects with Parkinson’s Disease suffering from
acute intermittent “off” episodes, with phased withdrawal of subjects from Tigan
to placebo. May 2010-ongoing.
Sub-Investigator. Schwarz Pharmaceuticals/SP921. A multicenter, randomized,
double-blind, placebo-controlled, 5-arm, parallel-group trial to assess rotigotine
transdermal system dose response in subjects with advanced-stage parkinson’s disease. February 2010-2012.
Sub-Investigator. Teva Pharmaceuticals. Andante: Add-On to Dopamine Agonists in
stage patients needing enhanced treatment efficacy. December 2010-ongoing.
Research Supervisor. Neurologix. Phase 2 Safety and Efficacy Study Evaluating
Glutamic Acid Decarboxylase Gene Transfer to Subthalamic Nuclei in Subjects with
Advanced Parkinson’s Disease. 2008-2009
Research Supervisor. Acadia Pharmaceuticals. ACP-103-015. A multi-centered,
open-labeled extension study of the safety and efficacy of ACP-103 in the treatment
of psychosis in Parkinson’s disease. 2008-2009
Research Supervisor. Acadia Pharmaceuticals. ACP-103-012. A multi-centered, double-blind, Placebo-controlled Trial to Examine the Safety and Efficacy of ACP-103
(pimavanserin tartrate) in the Treatment of Psychosis in Parkinson’s disease. 2008- 2009.
Research Supervisor. NIH/Parkinson’s Study Group/Weill-Medical College of
Cornell University. QE3. A randomized, double-blind, placebo-controlled trial of
Coenzyme Q10 in early Parkinson’s Disease. 2008-2009
Research Coordinator. Link Medicine Corp. LNK754. Phase-IIa. A Double-blind, placebo-controlled, randomized, multicentered, single-dose followed by multi-dosed study to explore the safety, tolerability, pharmacokinetics and pharmacodynamics of LNK-754 (a farnesyl transferase inhibitor) inpatients with early Parkinson’s disease that
have no disability requiring dopaminergic therapy. 2008-2009.
Research Coordinator. Schwarz Pharmaceuticals. SP 921. A multi-centered,
Randomized, double-blind, placebo-controlled trial to assess rotigotine transdermal
system response in subjects with advanced-stage Parkinson’s disease. 2007-2009.
Research Coordinator. Parkinson’s Study Group/Boehringer Ingelheim. 248-662
PramiBID. A randomized, double-blind, active and placebo controlled efficacy study of pramipexole given 0.5mg and 0.75 mg bid in early Parkinson’s Disease. 2006-2008.
Research Coordinator. NIH/Parkinson’s Study Group. PROGENI. Parkinson’s
Research: Organized Genetics Initiative. Genetic study in siblings with Parkinson’s
Disease. 2004-2009.
Research Coordinator. Eisai. E2007-A001-303. A multi-centered, open-
labeled extension study of the efficacy, safety and tolerability of E2007 in levodopa
treated Parkinson’s disease patients with motor fluctuations. 2007-2008,
Research Coordinator. Eisai, E2007-A001-302. A multi-centered, randomized,
double-blind, placebo-controlled, parallel group study of the efficacy, safety, and
tolerability of E2007 in levodopa treated Parkinson’s disease patients with motor
fluctuations.2007-2008.
Research Coordinator. Novartis. QUEST-PD. An assessment of quality of life in
Advanced PD patients with end of dose wearing off on levodopa therapy switched to
Stalevo therapy. 2005-2007.
Research Coordinator. Schwarz Biosciences. A multicenter, multinational, double-
blind, randomized placebo-controlled trial of efficacy and safety of rotigotine, a dopamine
agonist delivered by CDA patch in patients with early Idiopatchic Parkinson’s disease.
2002-2009.
PRESENTATIONS______________________________________________________________________________
• Nonmotor Symptoms in Parkinson’s Disease. Sponsored by Teva Pharmaceuticals and Medtronics. Chesapeake, VA. July 2012.
• Nonmotor Symptoms in Parkinson’s Disease. Sponsored by Teva Pharmaceuticals. Norfolk, VA. April 2012.
Role of a Nurse Practitioner and Current Clinical Trials at Ohio State University.
Sponsored by Valeant Pharmaceuticals. Central Ohio Parkinson’s Society. Columbus,
Ohio April 26, 2008
Current Clinical Trials and Research Process. Roles of a research participant and
Principal Investigator. Wallace-Kettering Neuroscience Institute. Kettering, Ohio. March 28, 2009
Diagnosis and Treatment of Parkinson’s Disease. Sponsored by Teva Pharmaceuticals.
Columbus, Ohio. February 20, 2008.
Questions and Answers on Parkinson’s Disease and Current Clinical Trials at Ohio State
University. Ohio University Athens Support Group. October 14, 2008.
Questions and Answers on Parkinson’s Disease and Current Clinical Trials at Ohio State
University. Knightsbridge Forum Support Group. April 9, 2009.
Clinical Trials in Early Parkinson’s Disease for the Treatment Team, Virginia Beach,
VA. June 2011.
PUBLICATIONS _______________________________________________________________________________
Kieburtz, Karl, Pramipexole given twice per day has similar efficacy to an equivalent
Dosage given twice per day. Manuscript. PSG. October 2009.
HONORS
Phi Eta Sigma, honor society
Alpha Gamma Delta, honor society
Scarlet and Gray Scholarship
Golden Key National Honor Society
Senior Leader, The Ohio State University Soccer Club
REFERENCES
Provided upon request
Contact this candidate